![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » Alynlam’s PH1 Therapy Wins Approval in Europe
Alynlam’s PH1 Therapy Wins Approval in Europe
November 24, 2020
Alynlam Pharmaceuticals has received marketing authorization in Europe for Oxlumo (lumasiran) as a treatment for primary hyperoxaluria type 1 (PH1), an ultra-rare orphan disease that can lead to renal failure.
Oxlumo is an RNA interference drug meant to halt production of oxalate, a disease-causing toxin that leads to PH1.
Alnylam has also submitted a New Drug Application to the FDA and has received a priority review with a target decision date of Dec. 3.
Upcoming Events
-
21Oct